Open an account

Oramed Pharmaceuticals

ORMP · NASDAQ

$4.15+$0.09 (+2.22%)TodayMarket closed ·
Prev close $4.06

About ORMP

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Employees
13
Headquarters
New York City, New York
Listed
Apr 1, 2002
Sector
Health Care
Industry
Pharmaceuticals
Website
oramed.com

ORMP key statistics

Market cap
168.89M
Price-earnings ratio
0.99
Dividend yield
—
Average volume
150.10K
Volume
142.35K
Open price
$4.06
High today
$4.22
Low today
$4.05
52 Week high
$5.47
52 Week low
$2.09

Oramed Pharmaceuticals (ORMP) at a glance

As of Oct 20, 2026, Oramed Pharmaceuticals (ORMP) shares are priced at $4.15, giving the company a market cap of 168.89M and a price-to-earnings ratio of 0.99.

Today the stock has traded between $4.05 and $4.22. The current price is 2.4% above the day's low and 1.7% below its high.

Volume so far is 142.35K shares, in line with the average of 150.10K shares a day.

Over the past year Oramed Pharmaceuticals has ranged from $2.09 to $5.47, and now sits 61% of the way up that range.

Oramed Pharmaceuticals met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported $1.84 per share against an estimate of $0.4386.

ORMP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 1095.6% on average.

  1. Q2 FY24: reported $0.26 per share against an estimate of $0.0102
  2. Q3 FY24: reported -$0.48 per share against an estimate of $0.0051
  3. Q4 FY24: reported $0.00 per share against an estimate of -$0.0255
  4. Q1 FY25: reported -$0.19 per share against an estimate of -$0.0102
  5. Q2 FY25: reported $0.31 per share against an estimate of -$0.0408
  6. Q3 FY25: reported $1.12 per share against an estimate of -$0.0408
  7. Q4 FY25: reported $0.2447 per share against an estimate of $0.00
  8. Q2 FY26: reported $1.84 per share against an estimate of $0.4386

ORMP news

  • Press releasePRNewswire

    Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

  • Press releasePRNewswire

    Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

  • Press releasePRNewswire

    Oramed and Lifeward Announce Strategic Transaction

  • Press releasePRNewswire

    Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

  • Press releasePRNewswire

    Oramed Reports Fiscal Third Quarter 2025 Financial Results

  • Press releasePRNewswire

    ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

  • Press releasePRNewswire

    Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

  • Press releasePRNewswire

    Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Similar companies

Companies in the same industry as Oramed Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.